Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 2/20 | 0.67 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.67 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.67 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.67 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.67 |
| ▸ | VNN1 | O95497 | 15/20 | 0.61 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.59 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | CES2 | O00748 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1237189 | 0.83 | SRD5A2 (0.79) | VNN1SRD5A2CNR1CES2 | |
| SCHEMBL27160486 | 0.81 | SRD5A2 (0.57) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL5338598 | 0.80 | KCNQ3 (1.00) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL5206266 | 0.80 | KCNQ3 (0.54) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL28565479 | 0.80 | SRD5A2 (0.73) | VNN1SRD5A2CNR1CES2 | |
| SCHEMBL20185793 | 0.79 | VNN1 (0.56) | VNN1SRD5A2CNR1 | |
| SCHEMBL21390490 | 0.79 | VNN1 (0.81) | VNN1 | |
| SCHEMBL1044812 | 0.79 | SRD5A2 (0.83) | VNN1SRD5A2CNR1CES2 | |
| SCHEMBL2941622 | 0.77 | SRD5A2 (0.81) | VNN1SRD5A2CNR1CES2 | |
| SCHEMBL9002252 | 0.77 | TSHR (0.64) | VNN1SRD5A2CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292157-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2019-09-26 | — | — | US | disclosed |
| US-20190292157-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2019-09-26 | — | — | US | disclosed |
| US-10308615-B2 | Heterocyclic compounds as inhibitors of Vanin-1 enzyme | PFIZER INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-10308615-B2 | Heterocyclic compounds as inhibitors of Vanin-1 enzyme | PFIZER INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180148420-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180148420-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180148420-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2018-05-31 | — | — | US | disclosed |
| EP-3303303-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | Pfizer Inc (US) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016193844-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016193844-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292157-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | VNN1, VAT1, CMA1 | KCNQ3 3200/4885KCNQ2 2714/4885KCNE1 772/4885 |
| US-10308615-B2 | Heterocyclic compounds as inhibitors of Vanin-1 enzyme | VNN1, MVD, VAT1 | KCNQ3 2558/4885KCNQ2 2170/4885KCNE1 759/4885 |
| US-20180148420-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | VNN1, CMA1, VAT1 | KCNQ3 2663/4885KCNQ2 2019/4885KCNE1 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.